The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Drug treatments in Alzheimer’s disease
Open accessAbstract
Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease (AD) and these act to control symptoms rather than alter the course of the disease. Studies of potential disease-modifying therapy have generally been undertaken in patients with clinically detectable disease, yet evidence suggests that the pathological changes associated with AD begin several years before this. It is possible that pharmacological therapy may be beneficial in this pre-clinical stage before the neurodegenerative process is established. Techniques providing earlier diagnosis, such as cerebrospinal fluid biomarkers and amyloid positron emission tomography neuroimaging, are key to testing this theory in clinical trials. Recent results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution. Such medicines could potentially delay the onset of dementia and would therefore markedly reduce its prevalence. However, we currently remain a good distance away from clinically available disease-modifying therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current treatments for AD, including cholinesterase inhibitors and memantine, offer limited symptom relief, especially in the early to moderate stages, but do not halt disease progression or address the underlying neurodegeneration.”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Four drugs (donepezil, memantine, galantamine, rivastigmine) are approved on the market and belong to two families: anticholinesterase inhibitors and anti-glutaminergics.”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [155]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,526
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 980
CNS immune privilege: hiding in plain sight
Carson, M. J., Doose, J. M., Melchior, B., Schmid, C. D., & Ploix, C. C. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00441.x · Cited by 838
Hyperinsulinemia and risk of Alzheimer disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2004) · Neurology · doi:10.1212/01.wnl.0000140292.04932.87 · Cited by 683
Chételat, G., Desgranges, B., Sayette, V. D. L., Viader, F., Eustache, F., & Baron, J. (2003) · Neurology · doi:10.1212/01.wnl.0000055847.17752.e6 · Cited by 606
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 602
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Donepezil for dementia due to Alzheimer's disease
Birks, J., & Harvey, R. J. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190 · Cited by 516
Morales, I., Guzmán-MartÃnez, L., Cerda-Troncoso, C., FarÃas, G. A., & Maccioni, R. B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00112 · Cited by 490
Overlap Between Pathology of Alzheimer Disease and Vascular Dementia
Kalaria, R. N., & Ballard, C. G. (1999) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199912003-00017 · Cited by 475
Petrovitch, H., White, L. R., Izmirilian, G., Ross, G. W., Havlik, R. J., Markesbery, W., Nelson, J., Davis, D. G., Hardman, J., Foley, D. J., et al. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00106-8 · Cited by 468
Sloane, P. D., Zimmerman, S. I., Suchindran, C., Reed, P. S., Wang, L., Boustani, M. A., & Sudha, S. (2002) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.23.100901.140525 · Cited by 467
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. J. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 421
Diabetes and the Risk of Multi-System Aging Phenotypes: A Systematic Review and Meta-Analysis
Lu, F.-P., Lin, K.-P., & Kuo, H.-K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004144 · Cited by 398
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 335
Extended results of the Alzheimer's disease anti‐inflammatory prevention trial
Breitner, J. C. S., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., Brandt, J., Craft, S., Evans, D. A., Green, R. C., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.014 · Cited by 327
Transport of Insulin Across the Blood-Brain Barrier: Saturability at Euglycemic Doses of Insulin
Banks, W. A., Jaspan, J. B., Huang, W., & Kastin, A. J. (1997) · Peptides · doi:10.1016/s0196-9781(97)00231-3 · Cited by 318
Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J. M., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006378.pub2 · Cited by 311
Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305
Lithium Trial in Alzheimer's Disease
Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04606 · Cited by 297
Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging
Mosconi, L., Berti, V., Glodzik, L., Pupi, A., Santi, S. D., & de Leon, M. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091504 · Cited by 279
Tau-aggregation inhibitor therapy for Alzheimer's disease
Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 279
Huang, H.-C., & Jiang, Z.-F. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0960 · Cited by 278
Memantine: A Review of Its Use in Alzheimer’s Disease
Robinson, D. M., & Keating, G. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00015 · Cited by 277
Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269
Hensley, K. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1414 · Cited by 258
Lipton, S. A. (2005) · Current Alzheimer Research · doi:10.2174/1567205053585846 · Cited by 256
Kennedy, A. M., Frackowiak, R. S. J., Newman, S. K., Bloomfield, P. M., Seaward, J., Roques, P., Lewington, G., Cunningham, V. J., & Rossor, M. N. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11270-7 · Cited by 250
Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease
Yarchoan, M. M., & Arnold, S. E. (2014) · Diabetes · doi:10.2337/db14-0287 · Cited by 234
CSF Biomarkers for Alzheimer's Disease Diagnosis
Arunagiri, A., Singh, P. K., Jacob, R. S., & Maji, S. K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/606802 · Cited by 215
Henley, D. B., May, P. C., Dean, R. A., & Siemers, E. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903044982 · Cited by 168
Midlife Vascular Risk Factors and Alzheimer's Disease: Evidence from Epidemiological Studies
Tolppanen, A., Solomon, A., Soininen, H. S., & Kivipelto, M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120802 · Cited by 143
Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., & Hansson, O. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100207 · Cited by 135
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Lessons from the AN 1792 Alzheimer vaccine: lest we forget
Robinson, S. R., Bishop, G. M., Lee, H., & Münch, G. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.020 · Cited by 102
Making Alzheimer's and dementia research fit for populations
Brayne, C., & Davis, D. H. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61803-0 · Cited by 100
Vascular risk factors and Alzheimer’s disease
O'Brien, J. T., & Markus, H. S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0218-y · Cited by 99
Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer′s Disease Treatment
Martı́nez, A., Gil, C., & Pérez, D. I. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/280502 · Cited by 95
Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
Prins, N. D., & Scheltens, P. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt220 · Cited by 79
Disease-modifying drugs in Alzheimer's disease
Scarpini, E. A., Galimberti, D., & Ghezzi, L. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s41431 · Cited by 74
The cholinergic deficit in Alzheimer's disease.
Whitehouse, P. J. (1998) · PubMed · Cited by 63
Areosa, S. A., & Sherriff, F. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154 · Cited by 60
Valenti, R., Pantoni, L., & Markus, H. S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0160-z · Cited by 57
Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?
Tariot, P. N., & Aisen, P. S. S. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09com05331 · Cited by 53
Intravenous immunoglobulin and Alzheimer’s disease: what now?
Loeffler, D. A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-70 · Cited by 52
Croisile, B., Auriacombe, S., Etcharry‐Bouyx, F., & Vercelletto, M. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2011.11.007 · Cited by 42
Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
Hasnain, M., & Vieweg, W. V. R. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140314153440 · Cited by 37
Tacrine therapy for the dementia of Alzheimer's disease.
Fc, M. (1994) · PubMed · Cited by 24
The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer’s Disease
Engelborghs, S., & Bastard, N. L. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/bf03262201 · Cited by 20
The interest of amyloid PET imaging in the diagnosis of Alzheimerʼs disease
Vandenberghe, R. R., Adamczuk, K., & Laere, K. V. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000036 · Cited by 20
Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?
Ravona-Springer, R., Davidson, M., & Noy, S. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/rravonaspringer · Cited by 18
Margaret McCartney: The “breakthrough” drug that’s not been shown to help in Alzheimer’s disease
McCartney, M. (2015) · BMJ · doi:10.1136/bmj.h4064 · Cited by 10
Research works printed but not linked: 1
- Mosconi, 2010, Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging, J Alzheimers Dis, 20, 843, 10.3233/JAD-2010-091504 · DOI
Cited by
Sorted by citations
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629
Interaction between Aβ and Tau in the Pathogenesis of Alzheimer’s Disease
Zhang, H., Wei, W., Zhao, M., Ma, L., Jiang, X., Pei, H., Cao, Y., & Li, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.57078 · Cited by 689
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“Drug development has targeted amyloid plaque formation, but other novel targets need to be explored [155].”
BackgroundBlood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc7031 · Cited by 304
Metadata
- Authors
- Briggs, R., Kennelly, S. P., & O’Neill, D.
- Affiliations
- Tallaght University Hospital (IE)
- Venue
- Clinical Medicine
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 16
- Issue
- 3
- Pages
- 247-253
- ISSN
- 1470-2118 (ISSN-L)
- PMC
- PMC5922703
- OpenAlex
- W2415242066
- Cited by
- 571
- References
- 76
- Citations by year
- 2026: 37 · 2025: 67 · 2024: 97 · 2023: 79 · 2022: 106 · 2021: 95 · 2020: 55 · 2019: 18 · 2018: 5 · 2017: 9 · 2016: 2
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Medicine (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, pharmacotherapy, disease-modifying therapy, symptomatic treatment, preclinical Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid PET, aducanumab, early diagnosis, dementia prevention
- MeSH terms
- Alzheimer Disease, Amyloid, Cholinesterase Inhibitors, Humans, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
